Boston Partners raised its position in Cencora, Inc. (NYSE:COR - Free Report) by 7.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,247,872 shares of the company's stock after buying an additional 379,090 shares during the quarter. Cencora makes up approximately 1.4% of Boston Partners' portfolio, making the stock its 7th biggest position. Boston Partners owned approximately 2.75% of Cencora worth $1,578,543,000 at the end of the most recent quarter.
A number of other hedge funds have also modified their holdings of COR. Deutsche Bank AG acquired a new position in shares of Cencora during the 2nd quarter valued at $286,673,000. Wedge Capital Management L L P NC increased its holdings in Cencora by 31.0% in the 2nd quarter. Wedge Capital Management L L P NC now owns 105,614 shares of the company's stock valued at $29,887,000 after purchasing an additional 24,968 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Cencora in the 2nd quarter valued at $841,000. Peachtree Investment Partners LLC purchased a new position in Cencora in the second quarter valued at about $2,204,000. Finally, Summit Global Investments purchased a new position in Cencora in the second quarter valued at about $2,283,000. 97.52% of the stock is currently owned by hedge funds and other institutional investors.
Insiders Place Their Bets
In other Cencora news, EVP Elizabeth Campbell sold 11,300 shares of Cencora stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $324.12, for a total transaction of $3,662,556.00. Following the sale, the executive vice president directly owned 19,455 shares in the company, valued at $6,305,754.60. The trade was a 36.74% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.38% of the stock is currently owned by company insiders.
Cencora Price Performance
COR opened at $348.60 on Thursday. Cencora, Inc. has a twelve month low of $244.82 and a twelve month high of $377.54. The firm has a market cap of $66.52 billion, a price-to-earnings ratio of 19.45, a PEG ratio of 1.81 and a beta of 0.58. The company has a current ratio of 0.94, a quick ratio of 0.59 and a debt-to-equity ratio of 3.01. The company has a fifty day simple moving average of $328.67 and a 200 day simple moving average of $317.17.
Cencora (NYSE:COR - Get Free Report) last issued its quarterly earnings data on Wednesday, November 4th. The company reported $4.66 EPS for the quarter, topping analysts' consensus estimates of $4.58 by $0.08. The firm had revenue of $88.35 billion for the quarter, compared to analyst estimates of $87.95 billion. Cencora had a net margin of 1.03% and a return on equity of 110.72%. The firm's revenue was up 5.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $3.84 EPS. Equities research analysts expect that Cencora, Inc. will post 19.58 EPS for the current fiscal year.
Cencora Increases Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 30th. Shareholders of record on Friday, November 13th will be paid a dividend of $0.66 per share. This is a boost from Cencora's previous quarterly dividend of $0.60. The ex-dividend date is Friday, November 13th. This represents a $2.64 dividend on an annualized basis and a yield of 0.8%. Cencora's payout ratio is 14.73%.
Analyst Ratings Changes
COR has been the topic of a number of recent research reports. UBS Group reduced their price objective on Cencora from $430.00 to $400.00 and set a "buy" rating on the stock in a research note on Friday, October 16th. Argus increased their target price on Cencora from $340.00 to $380.00 and gave the company a "buy" rating in a research note on Tuesday, October 20th. Wells Fargo & Company raised their target price on Cencora from $395.00 to $400.00 and gave the company an "overweight" rating in a report on Tuesday. Evercore reissued an "outperform" rating and set a $350.00 price target (up from $330.00) on shares of Cencora in a research report on Thursday, August 6th. Finally, Weiss Ratings raised Cencora from a "buy (b-)" rating to a "buy (b)" rating in a research report on Tuesday, October 6th. Thirteen analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $381.00.
View Our Latest Analysis on Cencora
Cencora Profile
(
Free Report)
Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical services company that connects pharmaceutical manufacturers with healthcare providers. Its core business includes sourcing and distributing medicines and other healthcare products to pharmacies, hospitals, health systems and other care providers. The company also provides services supporting specialty pharmaceuticals, including logistics, consulting and solutions for manufacturers and healthcare organizations. These services help manage the handling and delivery of complex medicines and support access to treatments.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cencora, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cencora wasn't on the list.
While Cencora currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.